Table 3.
Characteristics of cohort studies included in the meta-analysis
|
Schneble et al, 20126(n=87) |
Flemming et al, 20135(n=292) |
Wityk et al, 20147(n=96) |
Bervini et al, 20184(n=365) |
Flemming et al, 201816(n=202) |
SAIVMs cohort (n=300) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Never used ATT | Ever used ATT | Never used ATT | Ever used ATT | Never used ATT | Ever used ATT | Never used ATT | Ever used ATT | Never used ATT | Ever used ATT | Never used ATT | Ever used ATT | ||
| N | 71 (82%) | 16 (18%) | 252 (86%) | 40 (14%) | 74 (77%) | 22 (23%) | 294 (81%) | 71 (19%) | 160 (79%) | 42 (21%) | 238 (79%) | 62 (21%) | |
| Sex | |||||||||||||
| Women | 44 (62%) | 6 (38%) | 135 (54%) | 19 (48%) | 49 (66%) | 9 (41%) | 150 (51%) | 19 (27%) | 94 (59%) | 23 (55%) | 131 (55%) | 28 (45%) | |
| Men | 27 (38%) | 10 (62%) | 117 (46%) | 21 (52%) | 25 (34%) | 13 (59%) | 144 (49%) | 52 (73%) | 66 (41%) | 19 (45%) | 107 (45%) | 34 (55%) | |
| Mean age, years (SD) | 54·0 (16·5) | 68·4 (16·1) | 43·2 (18·6) | 62·4 (13·2) | 38·2 (15·9) | 53·0 (15·5) | 46·8 (18·2) | 62·4 (15·8) | 41·9 (15·7) | 51·4 (16·2) | 42·2 (15·1) | 54·5 (14·9) | |
| Presentation with haemorrhage | 11 (15%) | 0 | 69 (27%) | 5 (13%) | 23 (31%) | 5 (23%) | 102 (35%) | 14 (20%) | 64 (40%) | 6 (14%) | 47 (20%) | 5 (8%) | |
| Multiple CCM | 27 (38%) | 5 (31%) | 51 (20%) | 4 (10%) | 17 (23%) | 8 (36%) | 48 (16%) | 7 (10%) | 45 (28%) | 11 (26%) | 81 (34%) | 16 (26%) | |
| Brainstem CCM location | 20 (28%) | 3 (19%) | 21 (8%) | 7 (18%) | 21 (28%) | 9 (41%) | 57 (19%) | 8 (11%) | 52 (33%) | 9 (21%) | 25 (11%) | 9 (15%) | |
| Haemorrhage during follow-up | 9 (13%) | 0 | 31 (12%) | 1 (3%) | 14 (19%) | 1 (5%) | 33 (11%) | 1 (1%) | 47 (29%) | 4 (10%) | 18 (8%) | 1 (2%) | |
| Person-years of follow-up | 205 | 82 | 1776 | 247 | 468 | 122 | 813 | 134 | 609 | 170 | 2342 | 726 | |
Data are n (%) unless specified. CCM=cerebral cavernous malformations. ATT=antithrombotic therapy. SAIVMs=Scottish Audit of Intracranial Vascular Malformations.